title: The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children.
abstract: A double blind study was made on a group of 35 children, 8 of whom were allergic to Grass and 27 allergic to Pteronyssinus and Farinae Dermatophagoides. We verified the efficacy and tolerability of a new immunotherapy called E.P.D. (Enzyme Potentiated Desensitization). This particular immunotherapy consists in an intradermal injection of a mix made up of an allergic solution at extremely low doses and an enzyme, beta-glucuronidase. The vaccine is administered once a year, two weeks before pollen peaks for children with seasonal allergies and two times a year, in February and November, for children with non-seasonal allergies (Dermatophagoides). The results, statistically analyzed on the basis of a symptoms score, showed good clinical efficacy in patients affected by both seasonal and non-seasonal allergies. Due to the clinical effectiveness, easy administration and excellent tolerability of the immunotherapy, E.P.D. is particularly suited for treating or reducing allergic symptoms in allergic children.
authors.affiliation: Division Pediatric, Salesi Hospital of Ancona, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Caramia
authors.forename: F
authors.initials: F
authors.lastname: Franceschini
authors.forename: Z A
authors.initials: ZA
authors.lastname: Cimarelli
authors.forename: M S
authors.initials: MS
authors.lastname: Ciucchi
authors.forename: R
authors.initials: R
authors.lastname: Gagliardini
authors.forename: E
authors.initials: E
authors.lastname: Ruffini
mesh_terms: D000293:Adolescent; D000485:Allergens / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001249:Asthma / Q000209:etiology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000209:etiology / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000379:methods*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005966:Glucuronidase / Q000008:administration & dosage; D006801:Humans; D007271:Injections, Intradermal; D008297:Male; D008925:Mites / Q000276:immunology; D011058:Pollen / Q000276:immunology; D012221:Rhinitis, Allergic, Perennial / Q000209:etiology / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000209:etiology / Q000628:therapy*; D012449:Safety; D012621:Seasons; D016896:Treatment Outcome
chemical_list: D000485:Allergens; D005966:Glucuronidase